Recently, The U.S. Judicial Panel on Multidistrict Litigation (JPML) is set to hear oral arguments later this month to determine whether to consolidate and centralize multiple class action lawsuits filed against L’Oreal, which allege that its popular benzoyl peroxide (BPO) acne treatments, including CeraVe, are contaminated with benzene, a chemical known to cause cancer.
These lawsuits stem from concerns raised by a report from the independent testing laboratory Valisure, released in March 2024. The report revealed that benzene—a carcinogen—was present in levels in CeraVe and other BPO products that far exceed federally allowed limits, prompting a series of legal claims.
Benzoyl peroxide is widely used in acne treatments due to its effectiveness in killing acne-causing bacteria and reducing skin oil. However, since Valisure’s findings, consumers have been alarmed by the potential health risks posed by benzene in these products. Benzene exposure is linked to a range of serious health conditions, including various forms of leukemia, lymphoma, and other cancers.
In response to these mounting cases, plaintiffs have filed a motion to consolidate the L’Oreal-specific lawsuits into a Multidistrict Litigation (MDL) to streamline the legal process and ensure consistent rulings.
L’Oreal opposed the motion to centralize the cases, arguing that the lawsuits are limited in number and do not require an MDL. The company also contended that efforts to self-organize the litigation have been effective and that any perceived inefficiencies could be resolved without the intervention of the JPML. However, plaintiffs argue that the cases share substantial overlap in both legal and factual issues, with all cases naming L’Oreal as the defendant and relying on the same scientific findings regarding benzene contamination in BPO products.
